AWIQLI 1050 UNIT / 1.5 ML — DIN 02546213
INSULIN ICODEC : 1050 UNIT / 1.5 ML · NOVO NORDISK CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is AWIQLI?
AWIQLI 1050 UNIT / 1.5 ML contains INSULIN ICODEC : 1050 UNIT / 1.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02546213, held by NOVO NORDISK CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 13-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AWIQLI used for?
Once-weekly treatment of adults with diabetes mellitus to improve glycemic control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Insulin Icodec cost around the world?
Insulin Icodec is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 41 | 41 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 5 | 6 | NOK███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
49 pack listings across 47 brand entries and 3 price bases, refreshed 07 Sep 2026. Ranges span every Insulin Icodec pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Insulin Icodec in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Insulin Icodec — 3 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 3 | 3 | AWIQLI | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1050 UNIT / 1.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 1, 1.5 or 3 mL solution in a cartridge contained in a pre-filled multidose disposable FlexTouch pen. Available in 1 pen/pack. |
| Storage | Not explicitly detailed in the provided text snippet (refer to section 11), but standard insulin storage usually applies. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Insulin Icodec |
|---|---|
| ATC code | A10AE07 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02546213 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2546213 |
| Brand name | AWIQLI |
| Generic / active ingredient | INSULIN ICODEC : 1050 UNIT / 1.5 ML |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10AE07 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10AE |
| Current status | MARKETED |
| Status date | 13-Jun-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Subcutaneous once-weekly injection. Starting dose for insulin-naïve T2DM is 70 units. For switching from daily basal insulin, weekly dose is daily dose x 7. Optional 50% one-time additional dose for week 1.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
During episodes of hypoglycemia; patients who are hypersensitive to this drug or to any ingredient in the formulation.
Warnings and precautions
Hypoglycemia risk; do not mix with other insulins; do not use in insulin pumps; medication errors (do not confuse with daily insulin); rotate injection sites; never share pens.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AWIQLI | 700 UNIT | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02546205 |
| AWIQLI | 2100 UNIT / 3 ML | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02546221 |
2 · Same class — other molecules in ATC A10AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Insulin Glargine | BASAGLAR · LANTUS · SEMGLEE · TOUJEO DOUBLESTAR · +1 more | 11 | 8 | Yes |
| Insulin Icodec | AWIQLI | 3 | 3 | Yes |
| Insulin Degludec | TRESIBA | 3 | 3 | Yes |
| Insulin Glargine And Lixisenatide | SOLIQUA | 1 | 1 | Yes |
| Insulin Detemir | LEVEMIR FLEXTOUCH · LEVEMIR PENFILL | 2 | 0 | Not in Canada |
| Insulin (Human) | HUMULIN-U ULTRALENTE INJ 100UNIT/ML · NOVOLIN GE ULTRALENTE INJ SUS 100U/ML | 2 | 0 | Not in Canada |
| Insulin Degludec And Liraglutide | XULTOPHY | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10AB | Insulin (Beef) · Insulin (Human) · Insulin (Pork) · Insulin Aspart · Insulin Glulisine · +1 more | 40 | 24 |
| A10AD | Insulin (Human) · Insulin Aspart · Insulin Lispro | 31 | 9 |
| A10AC | Insulin (Human) · Insulin (Pork) | 13 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AWIQLI called?
The same molecule, Insulin Icodec, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Actrapid HM (ge) | Latin | South Africa |
| Insuman Rapid | Latin | Norway |
| Humulin NPH | Latin | Norway |
| Humulin NPH KwikPen | Latin | Norway |
| Insuman Infusat | Latin | Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.